Analysts forecast that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will announce earnings per share (EPS) of ($1.65) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Agios Pharmaceuticals’ earnings, with estimates ranging from ($1.75) to ($1.51). Agios Pharmaceuticals reported earnings of ($1.34) per share in the same quarter last year, which indicates a negative year over year growth rate of 23.1%. The business is expected to issue its next quarterly earnings report on Thursday, February 15th.

According to Zacks, analysts expect that Agios Pharmaceuticals will report full year earnings of ($6.59) per share for the current fiscal year, with EPS estimates ranging from ($6.69) to ($6.44). For the next financial year, analysts anticipate that the firm will post earnings of ($6.68) per share, with EPS estimates ranging from ($7.22) to ($5.84). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Agios Pharmaceuticals.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, beating the consensus estimate of ($1.78) by $0.19. The firm had revenue of $11.35 million for the quarter, compared to analysts’ expectations of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The company’s revenue was up 26.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.63) EPS.

A number of brokerages recently commented on AGIO. Zacks Investment Research cut Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday. SunTrust Banks reaffirmed a “buy” rating and issued a $80.00 target price on shares of Agios Pharmaceuticals in a report on Wednesday, October 4th. BidaskClub raised Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday. Credit Suisse Group raised their target price on Agios Pharmaceuticals from $61.00 to $66.00 and gave the stock an “outperform” rating in a report on Thursday, November 2nd. Finally, Cann reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a report on Tuesday, December 5th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $76.45.

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) traded down $6.31 during trading on Wednesday, reaching $68.80. The company had a trading volume of 1,175,800 shares, compared to its average volume of 710,070. Agios Pharmaceuticals has a one year low of $39.24 and a one year high of $76.02. The company has a market cap of $3,420.00, a PE ratio of -10.97 and a beta of 1.83.

In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 53,000 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $73.16, for a total transaction of $3,877,480.00. Following the sale, the chief executive officer now directly owns 53,000 shares of the company’s stock, valued at $3,877,480. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Scott Biller sold 2,146 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $62.69, for a total value of $134,532.74. The disclosure for this sale can be found here. Over the last three months, insiders have sold 80,130 shares of company stock worth $5,561,250. Insiders own 5.43% of the company’s stock.

Large investors have recently bought and sold shares of the business. QS Investors LLC purchased a new position in shares of Agios Pharmaceuticals during the second quarter valued at about $144,000. Cubist Systematic Strategies LLC grew its position in shares of Agios Pharmaceuticals by 1,041.0% during the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 3,123 shares in the last quarter. Bank of Montreal Can grew its position in shares of Agios Pharmaceuticals by 74.8% during the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 1,520 shares in the last quarter. Teacher Retirement System of Texas purchased a new position in shares of Agios Pharmaceuticals during the third quarter valued at about $225,000. Finally, S&CO Inc. purchased a new position in shares of Agios Pharmaceuticals during the third quarter valued at about $227,000. 94.32% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Agios Pharmaceuticals Inc (AGIO) Expected to Post Earnings of -$1.65 Per Share” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/17/agios-pharmaceuticals-inc-agio-expected-to-post-earnings-of-1-65-per-share.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.